Ibrucent 140 mg (ibrutinib)

Ibrucent-140mg is an anti-cancer medicine. It works by blocking an abnormal protein that signals cancer cells to multiply. Ibrucent Ibrutinib helps stop the spread of cancer cells.

Ibrutinib Withdrawal

Ibrutinib withdrawal refers to the symptoms experienced by patients who stopped taking ibrutinib. The symptoms are fever, fatigue, arthralgia, and myalgia. It happens when patient stop taking ibrutinib for a specific reason like toxicity, severe side effects or other personal reason.

Ibrutinib Life expectancy

The life expectancy after taking ibrutinib varies patient to patient. In a clinical trials it was found that 78% of the patients who have taken ibrutinib survived for seven years, and some patient survived for 8 years. This data was found on after 41 months of clinical trials. But this number may change depending on patient’s health condition and other medical history.

FAQ about Ibrucent-140mg ibrutinib

Q: What are Ibrucent 140 mg ibrutinib side effects?

Ibrucent has some side effects

• Difficulty having a bowel movement.
• heartburn or indigestion
• muscle stiffness or spasms
• small red or purple spots on the skin
• stomach discomfort, upset, or pain
• swelling or inflammation of the mouth

Q: What is the cost of ibrucent ibrutinib?

In the US ibrutinib costs $484 per capsule/tablet regardless of the strength 140mg. 

In the UK the cost of a year’s course of ibrutinib treatment is £55,954.50 (excluding VAT)

But you can get Ibrucent at an affordable price from us. for more information visit

for order, contact us

Q: What is the drug ibrutinib used for?

Ibrutinib is a type of targeted cancer drug. It is a treatment for mantle cell lymphoma. Chronic lymphocytic leukemia

Q: What cancers does ibrutinib treat?

A drug used alone or with other drugs to treat adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenstrom macroglobulinemia (a type of non-Hodgkin lymphoma), mantle cell lymphoma, or marginal zone lymphoma.

Q: How quickly does ibrutinib work?

Ibrutinib is a very effective CLL drug and provides evidence of rapid patient benefit concerning symptoms improving, lymph nodes decreasing, and blood counts improving. For some, a very good partial or clinical complete response can emerge clinically within 3-6 months

Dosage & Administration of Ibrucent 

MCL: 560 mg taken orally once daily (four 140 mg capsules once daily)
CLL and WM: 420 mg taken orally once daily (three 140 mg capsules once daily)
Capsules should be taken orally with a glass of water. The capsules should not be opened, broken, or chewed

Use in Pregnancy & Lactation

Pregnancy Category D
Based on animal data, Ibrutinib can cause fetal harm when administered to a pregnant woman. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.
It is not known whether Ibrutinib is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Ibrutinib, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use
The safety and effectiveness of Ibrutinib in pediatric patients have not been established.

Geriatric Use
No overall differences in safety or effectiveness were observed between elderly subjects and younger subjects. No overall differences in effectiveness were observed between these patients and younger patients. Cardiac adverse events (atrial fibrillation and hypertension), infections (pneumonia, urinary tract infection, and cellulitis), and gastrointestinal events (diarrhea and dehydration) occurred more frequently among elderly patients.

Connect our Facebook page to get update on oncology medicine.